Censavudine Drug Asset Due Diligence Report 2026

This Censavudine Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 18 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Censavudine can convert its Small molecule drug profile and RT biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Censavudine (query alias: Censavudine)
Modality / target	Small molecule drug; RT; RT inhibitors
Highest global status	Phase 2
Originator	Oncolys BioPharma, Inc., Yale University
Active developers	Oncolys BioPharma, Inc.

The MCP disease footprint includes Aicardi-Goutieres Syndrome, Amyotrophic Lateral Sclerosis, Frontotemporal Dementia. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT05613868	Phase 2	Terminated	4	Primary endpoint not disclosed in English source
NCT04993768	Phase 2	Completed	42	Primary endpoint not disclosed in English source
NCT04993755	Phase 2	Completed	42	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Transposon Announces Final Results from a Phase 2 Study of TPN-101 for the Treatment of C9orf72-Related Amyotrophic Lateral Sclerosis and/or Frontotemporal Dementia

Phase 2; n=42; evaluation: Positive. Reported fields: Vital Capacity(24-week) = -8.4 % ; Vital Capacity(24-week) = -16.5 %

Transposon Announces Interim Results from a Phase 2 Study of TPN-101 for the Treatment of Progressive Supranuclear Palsy to be Presented at the AD/PD™ 2024 International Conference on Alzheimer's and Parkinson's Diseases

Phase 2; n=not disclosed; evaluation: Positive. Reported fields: AE = Once-daily oral dosing of TPN-101 was well-tolerated at all dose levels. ; AE = Once-daily oral dosing of TPN-101 was well-tolerated at all dose levels.

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Censavudine addresses Aicardi-Goutieres Syndrome, Amyotrophic Lateral Sclerosis, Frontotemporal Dementia. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 3 matched transaction record(s) under the scope “asset-specific.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2020-06-15	Oncolys BioPharma has entered into an exclusive worldwide license agreement with Transposon Therapeutics for the nucleoside reverse transcriptase inhibitor OBP-601	Phase 2	US$300.0M stated total
2010-12-20	Bristol-Myers Squibb and Oncolys BioPharma Enter Global Licensing Agreement for Investigational HIV Compound	Phase 2	US$286.0M stated total
2006-06-27	Yale Licenses Potential Anti-HIV Agent to Oncolys BioPharma of Japan	Preclinical	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Didehydro-3'-deoxy-4'-ethynylthymidines and related compounds and their use in treating medical conditions”. The milestone feed surfaced a patent-application signal described as “Uses of taxifolin for respiratory health”. The milestone feed surfaced a patent-application signal described as “Line-1 inhibitors as cognitive enhancers”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Therapeutic index and off-target toxicity
Resistance biology and biomarker-defined patient selection
Differentiation from established and emerging standards

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO